Performance of Biotech IPOs Relative to Cash on Hand
This article was originally published in Start Up
Executive Summary
While the majority of the biotech IPO class of 2000 have plummeted from their highs, some continue to do comparatively well. To add an extra dimension to tracking the performance of these biotechs since their IPOs, we've plotted the ten companies with the most cash on hand post-IPO against a group with the least to see if those companies with stronger cash positions were better able than their peers to survive the current bear market.